Tech Company Financing Transactions
MyoGene Bio Funding Round
CureDuchenne Ventures participated in a funding round for MyoGene Bio. The round was announced by the company on 5/11/2023.
Transaction Overview
Company Name
Announced On
5/11/2023
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance development of MyoDys45-55, an AAV-delivered CRISPR/Cas9 gene editing approach that would be applicable to up to 50 % of all DMD patients.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7098 Miratech Dr 120
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
Our lead program is a gene editing therapy, MyoDys45-55, for Duchenne muscular dystrophy (DMD), a devastating muscle wasting disease. MyoGene Bio utilizes new technologies to have a strong positive effect on disease progression by targeting the underlying cause of disease. Our company philosophy is to make meaningful impacts on muscle diseases through our dedication to honesty, integrity, and innovation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Courtney Young
Co-Founder
April Pyle
Co-Founder
Melissa Spencer
Browse more venture capital transactions:
Prev: 5/11/2023: Cloverly venture capital transaction
Next: 5/11/2023: Datanomix venture capital transaction
Share this article
About Our VC Transactions Data
We report on every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs